The global Severe Combined Immunodeficiency (SCID) Diagnosis market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
SCID (severe combined immunodeficiency) is a group of rare disorders which occurs by mutations in genes involved in the development and function of infection-fighting immune cells. A detailed medical history and physical examination of the child are usually used to diagnose severe combined immunodeficiency (SCID). To help confirm the diagnosis, additional blood tests, including a total blood cell count, may be ordered.SCID (X-linked severe combined immunodeficiency) is an inherited immune system illness that affects virtually exclusively men. Because they lack the required immune cells to fight off some bacteria, viruses, and fungi, boys with X-linked SCID are prone to recurring and persistent illnesses.
The global severe combined immunodeficiency (SCID) diagnosis market refers to the market for diagnostic tests used to identify and diagnose infants with SCID, a rare genetic disorder that affects the immune system. SCID is characterized by a severe deficiency in both T cells and B cells, which are crucial for the body鈥檚 immune response. Infants with SCID are highly susceptible to severe infections and require early diagnosis and treatment.
The market for SCID diagnosis includes various laboratory-based tests and screening programs. Laboratory-based tests typically involve analyzing blood samples to assess the presence and function of immune cells. Commonly used tests include flow cytometry, T-cell receptor excision circle (TREC) analysis, and next-generation sequencing (NGS) methods to detect gene mutations associated with SCID. Additionally, newborn screening programs using dried blood spot samples have also been implemented in some regions to identify infants with SCID early on.
The global SCID diagnosis market is driven by several factors. One of the primary drivers is the increasing awareness and understanding of SCID among healthcare professionals and the general population. As a result, more infants are being tested for SCID, leading to earlier detection and prompt treatment initiation. Additionally, advancements in genetic testing technologies, such as NGS, have improved the accuracy and efficiency of SCID diagnosis.
Furthermore, government initiatives and newborn screening programs in various countries have contributed to the growth of the SCID diagnosis market. These programs aim to identify infants with SCID shortly after birth, allowing for early intervention and improved outcomes. For example, the implementation of SCID newborn screening programs in several U.S. states has significantly increased the detection of affected infants and facilitated early treatment.
Geographically, North America currently dominates the global SCID diagnosis market. This is primarily due to the higher prevalence of SCID in certain populations, well-established healthcare infrastructure, and the implementation of newborn screening programs. Europe is also a significant market, while other regions, such as Asia-Pacific and Latin America, are expected to witness growth as awareness and healthcare infrastructure continue to improve.
Key players in the global SCID diagnosis market include diagnostic laboratories, healthcare providers, and companies specializing in genetic testing. These companies focus on developing innovative testing methods, improving existing diagnostic tools, and collaborating with healthcare professionals and researchers to advance SCID diagnosis and management.
Overall, the global SCID diagnosis market is expected to witness substantial growth in the coming years, driven by factors such as increased awareness, advancements in genetic testing technologies, and the implementation of newborn screening programs. Early diagnosis and timely intervention are crucial for improving outcomes and quality of life for infants with SCID, emphasizing the importance of continued efforts in SCID diagnosis and management.
The 鈥淪evere Combined Immunodeficiency (SCID) Diagnosis Industry Forecast鈥� looks at past sales and reviews total world Severe Combined Immunodeficiency (SCID) Diagnosis sales in 2024, providing a comprehensive analysis by region and market sector of projected Severe Combined Immunodeficiency (SCID) Diagnosis sales for 2025 through 2031. With Severe Combined Immunodeficiency (SCID) Diagnosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Severe Combined Immunodeficiency (SCID) Diagnosis industry.
This Insight Report provides a comprehensive analysis of the global Severe Combined Immunodeficiency (SCID) Diagnosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Severe Combined Immunodeficiency (SCID) Diagnosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Severe Combined Immunodeficiency (SCID) Diagnosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Severe Combined Immunodeficiency (SCID) Diagnosis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Severe Combined Immunodeficiency (SCID) Diagnosis.
This report presents a comprehensive overview, market shares, and growth opportunities of Severe Combined Immunodeficiency (SCID) Diagnosis market by product type, application, key players and key regions and countries.
Segmentation by Type:
TREC Test
Complete Blood Count (CBC)
Genetic Test
Biochemical Test
Others
Segmentation by Application:
Hospital
Outpatient Center
Diagnostic and Research Laboratories
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
ARCHIMEDlife
PerkinElmer
Health Research, Inc
Winfertility
Portea Medical
LaCAR MDX Technologies
Labsystems Diagnostics Oy
Devyser Diagnostics
Revcovi
Leadiant Biosciences
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size (2020-2031)
2.1.2 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Severe Combined Immunodeficiency (SCID) Diagnosis by Country/Region (2020, 2024 & 2031)
2.2 Severe Combined Immunodeficiency (SCID) Diagnosis Segment by Type
2.2.1 TREC Test
2.2.2 Complete Blood Count (CBC)
2.2.3 Genetic Test
2.2.4 Biochemical Test
2.2.5 Others
2.3 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Type
2.3.1 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Market Share by Type (2020-2025)
2.4 Severe Combined Immunodeficiency (SCID) Diagnosis Segment by Application
2.4.1 Hospital
2.4.2 Outpatient Center
2.4.3 Diagnostic and Research Laboratories
2.4.4 Others
2.5 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Application
2.5.1 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Market Share by Application (2020-2025)
3 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Player
3.1 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Market Share by Player
3.1.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue by Player (2020-2025)
3.1.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Revenue Market Share by Player (2020-2025)
3.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Severe Combined Immunodeficiency (SCID) Diagnosis by Region
4.1 Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2020-2025)
4.2 Global Severe Combined Immunodeficiency (SCID) Diagnosis Annual Revenue by Country/Region (2020-2025)
4.3 Americas Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth (2020-2025)
4.4 APAC Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth (2020-2025)
4.5 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth (2020-2025)
4.6 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size Growth (2020-2025)
5 Americas
5.1 Americas Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2020-2025)
5.2 Americas Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Type (2020-2025)
5.3 Americas Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Region (2020-2025)
6.2 APAC Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Type (2020-2025)
6.3 APAC Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Country (2020-2025)
7.2 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Type (2020-2025)
7.3 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis by Region (2020-2025)
8.2 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Type (2020-2025)
8.3 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Forecast
10.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Region (2026-2031)
10.1.1 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Region (2026-2031)
10.1.2 Americas Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.1.3 APAC Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.1.4 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.1.5 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.2 Americas Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Country (2026-2031)
10.2.1 United States Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.2.2 Canada Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.2.3 Mexico Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.2.4 Brazil Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.3 APAC Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Region (2026-2031)
10.3.1 China Severe Combined Immunodeficiency (SCID) Diagnosis Market Forecast
10.3.2 Japan Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.3.3 Korea Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.3.4 Southeast Asia Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.3.5 India Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.3.6 Australia Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.4 Europe Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Country (2026-2031)
10.4.1 Germany Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.4.2 France Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.4.3 UK Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.4.4 Italy Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.4.5 Russia Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.5 Middle East & Africa Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Region (2026-2031)
10.5.1 Egypt Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.5.2 South Africa Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.5.3 Israel Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.5.4 Turkey Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
10.6 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Type (2026-2031)
10.7 Global Severe Combined Immunodeficiency (SCID) Diagnosis Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Severe Combined Immunodeficiency (SCID) Diagnosis Forecast
11 Key Players Analysis
11.1 ARCHIMEDlife
11.1.1 ARCHIMEDlife Company Information
11.1.2 ARCHIMEDlife Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.1.3 ARCHIMEDlife Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 ARCHIMEDlife Main Business Overview
11.1.5 ARCHIMEDlife Latest Developments
11.2 PerkinElmer
11.2.1 PerkinElmer Company Information
11.2.2 PerkinElmer Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.2.3 PerkinElmer Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 PerkinElmer Main Business Overview
11.2.5 PerkinElmer Latest Developments
11.3 Health Research, Inc
11.3.1 Health Research, Inc Company Information
11.3.2 Health Research, Inc Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.3.3 Health Research, Inc Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Health Research, Inc Main Business Overview
11.3.5 Health Research, Inc Latest Developments
11.4 Winfertility
11.4.1 Winfertility Company Information
11.4.2 Winfertility Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.4.3 Winfertility Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Winfertility Main Business Overview
11.4.5 Winfertility Latest Developments
11.5 Portea Medical
11.5.1 Portea Medical Company Information
11.5.2 Portea Medical Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.5.3 Portea Medical Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Portea Medical Main Business Overview
11.5.5 Portea Medical Latest Developments
11.6 LaCAR MDX Technologies
11.6.1 LaCAR MDX Technologies Company Information
11.6.2 LaCAR MDX Technologies Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.6.3 LaCAR MDX Technologies Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 LaCAR MDX Technologies Main Business Overview
11.6.5 LaCAR MDX Technologies Latest Developments
11.7 Labsystems Diagnostics Oy
11.7.1 Labsystems Diagnostics Oy Company Information
11.7.2 Labsystems Diagnostics Oy Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.7.3 Labsystems Diagnostics Oy Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Labsystems Diagnostics Oy Main Business Overview
11.7.5 Labsystems Diagnostics Oy Latest Developments
11.8 Devyser Diagnostics
11.8.1 Devyser Diagnostics Company Information
11.8.2 Devyser Diagnostics Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.8.3 Devyser Diagnostics Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Devyser Diagnostics Main Business Overview
11.8.5 Devyser Diagnostics Latest Developments
11.9 Revcovi
11.9.1 Revcovi Company Information
11.9.2 Revcovi Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.9.3 Revcovi Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Revcovi Main Business Overview
11.9.5 Revcovi Latest Developments
11.10 Leadiant Biosciences
11.10.1 Leadiant Biosciences Company Information
11.10.2 Leadiant Biosciences Severe Combined Immunodeficiency (SCID) Diagnosis Product Offered
11.10.3 Leadiant Biosciences Severe Combined Immunodeficiency (SCID) Diagnosis Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Leadiant Biosciences Main Business Overview
11.10.5 Leadiant Biosciences Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
